title: Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
abstract: BACKGROUND
  Overweight or obesity contributes to the development of type 2 diabetes mellitus (T2DM) and increases cardiovascular risk. Exenatide, a glucagon-like peptide-1 receptor agonist, significantly reduces glycated hemoglobin (A1C) and body weight and improves cardiovascular risk markers in patients with T2DM. As weight loss alone has been shown to reduce A1C and cardiovascular risk markers, this analysis explored whether weight loss contributed importantly to clinical responses to exenatide once weekly.
  
  
  METHODS
  A pooled analysis from eight studies of exenatide once weekly was conducted. Patients were distributed into quartiles from greatest weight loss (Quartile 1) to least loss or gain (Quartile 4). Parameters evaluated for each quartile included A1C, fasting plasma glucose (FPG), blood pressure (BP), heart rate, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
  
  
  RESULTS
  The median changes from baseline in body weight in Quartiles 1-4 were -6.0, -3.0, -1.0, and +1.0 kg, respectively. All quartiles had reductions in A1C (median changes -1.6, -1.4, -1.1, and -1.2%, respectively) and FPG (-41, -40, -31, and -25 mg/dL, respectively), with the greatest decreases in Quartiles 1 and 2. Most cardiovascular risk markers (except diastolic BP) and liver enzymes improved in Quartiles 1 through 3 and were relatively unchanged in Quartile 4. Higher rates of gastrointestinal adverse events and hypoglycemia were observed in Quartile 1 compared with Quartiles 2 through 4.
  
  
  CONCLUSIONS
  Exenatide once weekly improved glycemic parameters independent of weight change, although the magnitude of improvement increased with increasing weight loss. The greatest trend of improvement in glycemic parameters, cardiovascular risk factors including systolic BP, LDL-C, total cholesterol, and triglycerides, and in liver enzymes, was seen in the patient quartiles with the greatest reductions in body weight.
authors: Department of Endocrinology, Ochsner Medical Center, 1514 Jefferson Highway, 70121, New Orleans, LA, USA. lblonde@ochsner.org.
authors: Lawrence
authors: L
authors: Blonde
authors: Bristol-Myers Squibb/AstraZeneca, San Diego, CA, USA. rpencek@gmail.com.
authors: Richard
authors: R
authors: Pencek
authors: Bristol-Myers Squibb/AstraZeneca, San Diego, CA, USA. lmacconell@gmail.com.
authors: Leigh
authors: L
authors: MacConell
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage*; D012307:Risk Factors; D014688:Venoms / Q000008:administration & dosage*; D015431:Weight Loss / Q000187:drug effects* / Q000502:physiology
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide
references: Lancet. 2013 Jan 12;381(9861):117-24
references: 23141817
references: Mol Med Rep. 2014 Nov;10(5):2447-52
references: 25190495
references: Diabetes Care. 2012 Jun;35(6):1364-79
references: 22517736
references: Diabetes Care. 2014 Jan;37 Suppl 1:S14-80
references: 24357209
references: N Engl J Med. 2013 Jul 11;369(2):145-54
references: 23796131
references: Diabetes. 2007 Feb;56(2):438-43
references: 17259389
references: Am J Epidemiol. 2014 Jun 1;179(11):1353-65
references: 24786797
references: J Clin Endocrinol Metab. 2011 May;96(5):1301-10
references: 21307137
references: Diabetes Care. 2007 Jun;30(6):1374-83
references: 17363746
references: Circulation. 2014 Jan 21;129(3):e28-e292
references: 24352519
references: Cardiovasc Diabetol. 2014;13:69
references: 24693878
references: Am J Med. 2010 May;123(5):468.e9-17
references: 20399326
references: Clin Ther. 2007 Jan;29(1):139-53
references: 17379054
references: Lancet. 2008 Oct 4;372(9645):1240-50
references: 18782641
references: Lancet. 2010 Jun 26;375(9733):2234-43
references: 20609969
references: Cardiovasc Diabetol. 2014;13:132
references: 25194961
references: Int J Obes (Lond). 2012 Jun;36(6):843-54
references: 21844879
references: J Diabetes Investig. 2013 Jan 29;4(1):53-61
references: 24843631
references: Diabetes Care. 2012 Feb;35(2):252-8
references: 22210563
references: Diabetes Obes Metab. 2006 Jul;8(4):419-28
references: 16776749
references: Diabetes Obes Metab. 2013 Jan;15(1):42-54
references: 22862847
references: Lancet. 2012 Jun 16;379(9833):2270-8
references: 22683137
references: Endocr Pract. 2013 Mar-Apr;19(2):327-36
references: 23598536
references: Diabetes Care. 2013 May;36(5):1368-76
references: 23275363
references: Metabolism. 2014 Aug;63(8):1041-8
references: 24933399
references: Lancet. 2010 Aug 7;376(9739):431-9
references: 20580422
references: Obesity (Silver Spring). 2014 Aug;22(8):1880-7
references: 24706434
references: Diabetes Obes Metab. 2006 Jul;8(4):436-47
references: 16776751
references: N Engl J Med. 2006 Dec 7;355(23):2427-43
references: 17145742